
"I saw a patient who's no longer a patient, and there's nothing better than that."
Where I see patients (2)
Selected research
-
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.
Blood cancer discovery
-
Therapy by omission: observation as a strategy in JMML.
Blood
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Blood
Clinical trials
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Recruiting
More about this studyContact me
Fetal surgery firsts
The first open fetal surgery in the world was performed at UCSF in the early 1980s.
